Dr. Cristiana Costa
Overview
An interest in biological sciences and giving back to the community drove me to medical school, but it has been a desire to advance the field of hematologic malignancies, specifically Multiple Myeloma, that brings me to Duke Health. Cancer is a life-altering diagnosis. With a strong, competent team caring for a patient, there can be many success stories. My goal is to empower my patients to understand their diagnosis and how to manage their disease while providing them with many treatment options along the way.
Dr. Costa is rated as an Experienced provider by MediFind in the treatment of Plasmacytoma. Her top areas of expertise are Relapsed Refractory Multiple Myeloma (RRMM), Multiple Myeloma, Smoldering Multiple Myeloma, Hereditary Cerebral Amyloid Angiopathy, and Bone Marrow Aspiration.
Her clinical research consists of co-authoring 1 peer reviewed article. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- EPO
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- OTHER COMMERCIAL
- OTHER MEDICARE PART D
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- HMO
- POS
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
2400 Pratt St, Durham, NC 27705
2400 Pratt St, Durham, NC 27705
Additional Areas of Focus
Dr. Costa has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Duke Blood Cancer Center
As a physician and scientist, my ultimate goal is to translate research findings from bench to beside to improve patient care. I focus my research and clinical work on treating blood and bone marrow cancers. Most of the patients in my clinic are blood and bone marrow transplant patients and patients with plasma cell diseases such as multiple myeloma, amyloidosis, POEMS syndrome, and Waldenstrom's macroglobulinemia. The research interests in my lab are on the development of new approaches to enhance hematopoietic stem cell engraftment and reconstitution following blood and bone marrow transplant. Dr. Kang is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Schnitzler Syndrome, Bone Marrow Aspiration, and Bone Graft.
University Of North Carolina At Chapel Hill
Eben Lichtman is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Lichtman is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Smoldering Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration. Dr. Lichtman is currently accepting new patients.
Duke Blood Cancer Center
Since studying basic immunology prior to beginning my clinical training, I have been deeply interested in applying immunological perspective for the treatment of cancers including hematologic malignancies. Interestingly emerging immunotherapies showed very promising results in recent years. In my clinic, I treat patients with multiple myeloma which is one type of cancer arising from plasma cells. My research will focus on developing early phase clinical protocols utilizing novel cellular therapy approach and also improving the outcomes of blood and marrow transplantation. My ultimate goal is to provide better treatment options than the current standard approach to patients. Dr. Choi is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Multiple MyelomaDr. Costa isDistinguished. Learn about Multiple Myeloma.
- Relapsed Refractory Multiple Myeloma (RRMM)
- Advanced
- Cardiac AmyloidosisDr. Costa isAdvanced. Learn about Cardiac Amyloidosis.
- Cerebral Amyloid AngiopathyDr. Costa isAdvanced. Learn about Cerebral Amyloid Angiopathy.
- Glyceraldehyde-3-Phosphate Dehydrogenase Deficiency
- GTP Cyclohydrolase 1 DeficiencyDr. Costa isAdvanced. Learn about GTP Cyclohydrolase 1 Deficiency.
- Hereditary Cerebral Amyloid Angiopathy
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Experienced
- Acute Myeloblastic Leukemia with Maturation
- Acute Myeloblastic Leukemia without Maturation
- Acute Myeloid Leukemia (AML)Dr. Costa isExperienced. Learn about Acute Myeloid Leukemia (AML).
- Bone Marrow AspirationDr. Costa isExperienced. Learn about Bone Marrow Aspiration.
- Childhood Acute Myeloid LeukemiaDr. Costa isExperienced. Learn about Childhood Acute Myeloid Leukemia.
- Diffuse Large B-Cell Lymphoma (DLBCL)Dr. Costa isExperienced. Learn about Diffuse Large B-Cell Lymphoma (DLBCL).